We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tern Plc | LSE:TERN | London | Ordinary Share | GB00BFPMV798 | ORD 0.02P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -3.57% | 2.70 | 2.60 | 2.80 | 2.85 | 2.70 | 2.85 | 279,166 | 08:02:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 66k | -10.45M | -0.0269 | -1.04 | 10.88M |
Tern PLC (TERN) Tern PLC: New commercial order for FundamentalVR 25-Jul-2019 / 15:25 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 25 July 2019 Tern Plc ("Tern" or the "Company") New commercial order for FundamentalVR Tern Plc (AIM: TERN), the investment company specialising in the Internet of Things ("IoT"), is pleased to announce that FVRVS Limited ("FundamentalVR"), a leading virtual reality ("VR") training and data analysis technology platform, and one of Tern's existing portfolio companies, has secured an order of approximately GBP0.5 million to create an additional VR simulation, for one of the world's leading pharmaceutical companies. This is the second order in a planned series of virtual reality simulations specifically designed to support that pharmaceutical company's ambitions to accelerate the safe and compliant use of their products. The majority of this order will be completed during 2019. FundamentalVR's award winning platform combines immersive virtual reality with cutting-edge haptics (the sense of touch) to create low-cost and scalable simulation experiences, to offer a new way to allow skills development for surgeons and medical professionals. This second implementation will be used to teach surgeons how to practice safe administration of the product, enabling the individual surgeon to benchmark their skills against a recommended approach to provide data they can use to improve patient outcomes. The multi-stage virtual reality approach has become the template for product education by the pharmaceutical client, utilising FundamentalVR's virtual reality with haptics platform. Tern CEO, Al Sisto, said, "We're pleased to note this follow-on order for FundamentalVR. We have found that the adoption of its platform has been key in accelerating the competency and confidence surgeons now have when it comes to using medical devices and practicing innovative medical procedures, with FundamentalVR having the ability to shorten the time for market acceptance. We look forward to announcing further adoption of the platform in due course." **ENDS** Enquiries Tern plc Via Newgate Communications Al Sisto, CEO Sarah Payne, Finance Director Allenby Capital Limited Tel: 020 3328 5656 (Nomad and Joint broker) David Worlidge/Alex Brearley Whitman Howard Tel: 020 7659 1234 (Joint broker) Nick Lovering/Christopher Furness Newgate Communications Tel: 020 3757 6880 PR Elisabeth Cowell/Fiona Norman ISIN: GB00BFPMV798 Category Code: MSCH TIDM: TERN LEI Code: 2138005F87SODHL9CQ36 Sequence No.: 14688 EQS News ID: 847089 End of Announcement EQS News Service
(END) Dow Jones Newswires
July 25, 2019 10:25 ET (14:25 GMT)
1 Year Tern Chart |
1 Month Tern Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions